Navigation Links
CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform
Date:8/5/2009

CARLISLE, Mass., Aug. 5 /PRNewswire/ -- CapitalBio Corporation and VigeneTech Inc. have announced the launch of a fully integrated microarray solution platform. CapitalBio Corp., a developer and marketer of diagnostic biochips and advanced microarray instrument systems, in collaboration with VigeneTech, developers of novel image analysis, automation, and instrumentation software, now offers a platform that combines the superior performance and "one-click" automation of the MicroVigene(TM) image analysis suite with the long-established performance of CapitalBio's LuxScan(TM) microarray scanners.

The LuxScan(TM) system with MicroVigene(TM) is well-suited for diagnostic and high-throughput DNA, protein, antibody, and miRNA array applications. The embedded image acquisition control, combined with the synchronized image analysis of the LuxScan/MicroVigene platform, offers unparalleled speed, sensitivity, and image data of superior accuracy. VigeneTech's customized quality control processes and flexible architecture ensure robust automation while maintaining the flexibility to meet the quality and performance demands of clinical and pre-clinical array applications.

"The MicroVigene software from VigeneTech bring a new dimension to the analysis possibilities realizable with LuxScan microarray scanners, opening up a suite of advanced applications for protein analysis, DNA analysis and cell analysis," noted Dr. Jing Cheng, CEO and Founder of CapitalBio. "The LuxScan scanners have a wide depth of field which can capture accurate images from different types of microarrays and from tissue arrays. The combination of these scanning advantages with MicroVigene software provides enhanced analysis possibilities. This fully customized application brings image analysis to a new level of control. Irregular spots and offset spots are all found easily and then analyzed with the highest accuracy."

"Sensitivity, accuracy and reliability are the key drivers for any microarray technology to be adopted in the field, especially for diagnostic and high-throughput drug discovery applications. VigeneTech has the image analysis solutions to meet these stringent requirements," Dr. Minzi Ruan, CEO of VigeneTech commented. "The integration of MicroVigene with the reputable LuxScan scanner represents a complete turn-key system, with the flexibility and extensibility to accommodate any new diagnostic or research microarray applications and will be a superior platform for deploying diagnostic arrays in the field."

ABOUT VIGENETECH

VigeneTech is a leading provider of automated image and data analysis software solutions. VigeneTech offers novel scientific software and customized solutions for biomarker discovery, drug development, diagnostic and other clinical and pre-clinical applications. Our product platforms include: VigeneTech's MicroVigene(TM) for microarray image analysis, which delivers unprecedented accuracy and reproducibility; and VigeneTech's CellVigene(TM), which provides superior signal extraction and quantitation of cell/tissue-based images for diagnostic and pre-clinical high-content applications. For more information, visit http://www.vigenetech.com.

ABOUT CAPITALBIO

CapitalBio Corporation is China's leading developer and marketer of biochips, microarray-related instruments and microarray services. Its range of LuxScan(TM) dual and single laser microarray scanners are used widely in Europe, the Americas and Asia. It also develops active biochips and dedicated software for data analysis and biomedical data management. The company, founded in 2000, currently has nearly 400 employees and is closely linked to the National Engineering Research Centre for Beijing Biochip Technology. Visit http://www.capitalbio.com for more information.

    Contact:

    Minzi Ruan, Ph.D.
    CEO, VigeneTech Inc.
    Carlisle, Massachusetts
    Tel: 978 371 5959
    minzi@vigenetech.com

    Chen REN
    Assistant Director, Business Development
    CapitalBio Corporation
    Tel: +86 10 8071 5888 Ext. 8217
    chren@capitalbio.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE CapitalBio Corporation; VigeneTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):